Taxonomy, Treatment, Targets and Remission: Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions (R-10250)

Autoimmune, inflammatory and allergic diseases are common chronic diseases that significantly affect the wellbeing of millions of people around the globe and pose a substantial burden to healthcare systems. While different treatments are available, response and disease progression in individual patients remain unpredictable. Therefore, a deeper understanding of the cellular mechanisms driving disease development is urgently needed. In a never-before-seen effort to bring together experts from different medical fields, profiling technologies, systems biology and bioinformatics with specialists from innovative small- and medium-sized enterprises (SMEs) and leading pharmaceutical companies, 3TR – a public-private partnership project under the IMI umbrella – sets out to fundamentally increase our knowledge of the molecular pathways and mechanisms linked to response and non-response to therapy in seven different immune-mediated, allergic and inflammatory diseases: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (incl. ulcerative colitis and Crohn's disease), asthma, and chronic obstructive pulmonary disease. Despite their heterogeneity, recent studies have shown that on the molecular level certain patterns are shared by patients across these diseases, thus suggesting they may also share pathways of response to treatment and disease progression. The project will facilitate stratification and identification of molecular patterns that better predict response or non-response to therapy. This comprehensive approach will help identify biomarkers to improve patient management within these diseases.

Keywords:AUTOIMMUNE DISEASES, multiple sclerosis

Disciplines:Autoimmunity

Project type:Collaboration project